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Abstract The risk of venous thromboembolism (VTE) in patients who survive the first years after
a cancer diagnosis after the acute effects of disease and treatment in comparison to a
similar background population has been sparsely investigated. The aim of the study
was to investigate if incidence rates (IRs) of VTE differed in patients who were alive at
least 2 years after a cancer diagnosis without VTE comparedwith cancer-free references
in a population-based cohort study. The study entry was 2 years after a first cancer
diagnosis. For each cancer-exposed subject, five reference subjects were identified
within the cohort. The IRs were calculated as number of VTEs per 1,000 person years
(103 p-y) in total and in distinct cancer types and corresponding reference subjects.
Incidence rate ratios (IRRs) were calculated by Poisson’s regression. During a mean
follow-up of 5.3 years, 110 VTEs occurred among the 7,288 cancer-exposed subjects
and 321 VTEs occurred among the 36,297 identified reference subjects. The IR of VTE
was higher for cancer-exposed subjects compared with reference subjects, IRs
3.7  103 p-y, 95% CI: 3.1 to 4.5 and 1.9  103 p-y, 95% CI: 1.7 to 2.2, respectively.
IRs of VTE in most solid cancer types declined to almost the same level as in the
reference subjects 2 years after cancer diagnosis, but remained higher in hematological
cancers, IRR 4.0, 95% CI: 2.0 to 7.8.
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Introduction
Cancer entails a higher risk of venous thromboembolism
(VTE) and the risk varies due to patient-specific, cancer-
specific, and treatment-related risk factors, and depends on
time since cancer diagnosis.1–8 The risk of VTE is highest in
the months shortly before and after cancer diagnosis and
attenuates considerably by time since cancer diagno-
sis.2,7,9–11 However, the incidence of VTE among cancer
patients who survive the first years after a cancer diagnosis
in comparison to the background population is sparse.
The risk of VTE in association with a cancer diagnosis is
strongly related to cancer type, and consequently the risk of
VTE in patients who are alive when the acute effect of the
cancer and its treatments on the risk of VTE attenuates may
also differ according to cancer type. Several studies on single
entities of cancer have reported risk of VTE associated with
cancer and typically the occurrence of VTE was described as
the cumulative incidence proportions of VTE with reference
to the time since cancer diagnosis.10–21 This measure is,
however, not suitable for the estimation of the VTE risk for
cancer patients who pay their last visit in the oncologic
outpatient clinic after relapse-free survival some years after
the diagnosis. If the VTEs in close proximity to the cancer
diagnosis are included, this estimate will be too high. For
patients who are alive after the acute effect of cancer and the
associated treatments have faded, the early events in the
cancer group should not be included when estimating their
future risk of VTE.
The Scandinavian Cancer and Thrombosis (STAC) cohort
contains person-time data for 144 952 persons amongwhom
19,757 cancers occurred during a median follow-up of
14.1 years.22 The size of the STAC cohort enables matching
to cancer-free subjects within the cohort and thus compar-
ison of VTE incidence rates (IRs) in subjects with different
initial cancer types.
The objective of this study was to investigate the inci-
dence of VTE in cancer-exposed subjects who survived the
first 2 to 5 years after cancer diagnosis without VTE. These
patients contributed to person–time at risk of first lifetime
VTE from 2 years after cancer diagnosis and onwards. IRs of
VTE were estimated for the cancer-exposed subjects overall
and in distinct types of cancer and were compared with the
IRs of VTE in cancer-free reference subjects starting at
different time points from initial cancer diagnosis.
Methods
Study Population
Prospectively collected data from three large population-
based studies were merged in the STAC cohort. The Danish
Diet, Cancer andHealth (DCH) Study contributedwith 57,053
participants; the Norwegian studies, the Tromsø Study
(Tromsø 4), and the Nord-Trøndelag Health Study (HUNT2)
contributed with 27,158 and 65,237 participants, respec-
tively. In the two Norwegian cohorts, all inhabitants of
Tromsø and Nord-Trøndelag between 25 to 99 and 19 to
103 years of age, respectively, were invited to participate,
while in the DCH study all inhabitants of the cities Copenha-
gen and Aarhus aged 50 to 64 were invited. The rates of
participation were between 35% and 77%, highest in
Tromsø.23–25 Enrolment took place from 1993 through
1997, and subjects with prior cancer or VTE were excluded
from the STAC cohort, leaving 144,952 participants to follow
up. By informed, written consent at enrolment, every parti-
cipant permitted linkage to national registries by the civil
personal registration (CPR) number, which is a unique id
assigned to every citizen at birth or immigration by the
respective national civil registration systems. They are con-
tinuously updated on vital and emigration status, which
means no de facto loss to follow-up in studies taking advan-
tage of the CPR numbers. Recently, the STAC cohort’s profile
including age-specific IRs of cancer and VTEwas published.22
The age-standardized rates of cancer in the three original
cohorts did not differ from the respective general popula-
tions. In this study,we included all cancer patients, whowere
alive and free of previous VTE 2 years after a first cancer
diagnosis. Patients in the STAC cohort with a cancer diag-
nosis after last follow-up for validated VTEs (n ¼ 301) were
excluded, leaving in a total of 7,645 patients with a former
cancer diagnosis eligible for this study.
Identification of Cancer-Exposed Subjects and
Sampling of Reference Subjects
In both Denmark and Norway, cancer registration is manda-
tory by law and the respective national cancer registries
provide high-quality data on individual cancer diagnosis
date and cancer typeby ICD-10 codes, which identified cancer
patients in this study.26–30 All cancer types were included
exceptnonmelanomaskincancers (ICD-10 C44.x) andchronic
myeloproliferative/myelodysplasticdiseases (ICD-10 C92.1–C
45.9 and D 45.0–47.3) as this group was not registered in the
national cancer registries before 2004. If a new cancer was
registered by an ICD-10 code different from the index cancer
after the study entry, this was considered a second cancer.
Cancer stagewas registered by national classification systems,
the Federation of Gynecology and Obstetrics (FIGO) classifica-
tion (for gynecological tumors), Duke’s classification (for color-
ectal cancer), or the Tumor, Node, Metastasis (TNM)
classification. We have recently developed an algorithm for
mappingofcancer stages in thedifferentclassificationsystems
to a “localized, regional spread, distant metastasis” terminol-
ogy according to recommendations from the International
Cancer Benchmark Partnership.31,32
For each cancer-exposed subject, we intended to identify
five reference subjects in the STAC cohort free of previous
cancer and VTE at the index date. Reference subjects were
matched on age at study entry, sex, and original study to
control for confounding by these factors, the latter due to
different points of administrative censoring in the three
original cohorts. In case no reference subjects were identified,
the cancer-exposed subject was excluded from the study.
Outcome
All potential first-time, symptomatic VTE events (pulmonary
embolism and deep vein thrombosis covered) in the STAC
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cohort were identified before merging by linkage of CPR
numbers to hospital discharge registries and radiology pro-
cedure registries in Norway and the Danish National Patient
registry and the Danish national Cause of Death Registry in
Denmark. Subsequently all VTE events were validated by
review of medical records; typical symptoms of VTE, bio-
chemical tests and diagnostic images, and provoking factors
were noted. AVTEwas confirmed in caseswhere a diagnostic
test following typical clinical symptoms confirmed a VTE as
described in detailed in previous publications.33–35 Last
follow-up for VTE was in 2012 in the Tromsø Study, in
2008 in DCH, and in 2007 in HUNT2.
Statistics
The study entry was set to 730.50 days after first cancer
diagnosis and the corresponding index date for reference
subjects. Participants contributed with cancer–exposed and
corresponding never-cancer–exposed person-time until
VTE, end of follow-up for VTE, second cancer diagnosis,
emigration or death, and for reference subjects a first cancer
diagnosis, whichever camefirst.We calculated IRs as number
of VTEs per 1,000 person-years (103 p-y) for different
time periods after cancer diagnosis: the entire study period
(i.e.,  2 years after cancer diagnosis) and 3 years after study
entry (i.e., 5 years after cancer diagnosis) and at corre-
sponding points in reference subjects. Incidence rate differ-
ences (IRD) and associated 95% confidence intervals (CI)
were calculated to describe absolute differences in VTE
occurrence in cancer-exposed subjects and reference sub-
jects. Estimates were calculated for all cancers combined and
for the most common single entities of cancer among the
cancer-exposed subjects: hematological cancers, colorectal,
breast, and prostate cancers. All other solid cancer types
were combined in one group with lung, bladder, and uterine
cancers being the most common cancer types.
Relative measures of association were calculated as inci-
dence rate ratios (IRR) with associated 95% CIs. Age was
included as a continuous variable represented as a restricted
cubic spline variable with four knots in the Poisson regres-
sion model to control for aging since study entry/index date.
The association between initial cancer stage (at the time of
diagnosis) and VTEs in the cancer-exposed subjects was
assessed in separate analysis.
To illustrate the absolute riskof VTE, cumulative incidence
proportions of VTE since study entry were calculated for
reference subjects and for cancer overall. We created vari-
ables containing the cumulative incidences of each of the
censoring events; death and second cancer were treated as
competing risks in the cancer exposed, while death and first
cancer were treated as competing risks in reference subjects.
The significance of the difference between provoked VTEs
in cancer-exposed subjects compared with reference sub-
jects was tested by using chi-square test.
Results
Mean age for the cancer-exposed subjects at study entry (i.e.,
2 years after cancer diagnosis) was 68.9 years, and 49.5%
weremales. The vastmajority of the cancer-exposed subjects
had initially (i.e., at the time of diagnosis) localized or
regional spread cancer (►Table 1). During the study period,
a cancer diagnosis occurred in 4,855 (13.4%) of the reference
subjects. A second cancer diagnosis occurred in 770 (10.6%)
of the cancer-exposed subjects during the study period and
three VTEs occurred after this diagnosis. In total 431 VTEs
occurred during the study period with a mean follow-up of
5.3 years (i.e., 7.3 years after cancer diagnosis). A total of 110
of the VTEs occurred among the cancer-exposed subjects; 77
of these occurred more than 1 year after study entry (i.e.,
more than 3 years after cancer diagnosis) and 44 occurred
later than 3 years after study entry (i.e., more than 5 years
after cancer diagnosis).
In total, 36,297 reference subjectswere identified. For7,238
of the 7,645 identified cancer-exposed subjects, five reference
subjects were identified, but despite the size of the STAC
cohort, no reference subjects were available for 357 cancer-
Table 1 Baseline characteristics for the cancer-exposed subjects and the reference subjects
N Male Female Mean age,
y (range)
SD
mean
age
Localized
disease %
(n)
Regional
spread %
(n)
Distant
metastasis %
(n)
Unknown
stage %
(n)
Reference
subjects
36,297 16,506 19,791 65.0
(22.0–97.0)
9.5 – – – –
Breast 1,703 9 1,694 63.5
(35.5–97.1)
8.9 51
(872)
36
(621)
2
(28)
11
(182)
Prostate 1,331 1,331 0 69.0
(44.5–97.4)
6.9 49
(658)
10
(130)
10
(127)
31
(416)
Colorectal 1,122 561 561 67.8
(38.0–93.1)
8.9 39
(442)
50
(559)
5
(57)
6
(64)
Other solid
cancer
2,571 1,122 1,449 64.3
(23.9–94.9)
10.7 64
(1,636)
16
(420)
7
(179)
13
(336)
Hematological 561 295 266 65.7
(22.5–96.5)
11.3 na na na na
Abbreviations: na, not available; SD, standard deviation.
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exposed subjects which were excluded from the study. The
majority of thesewere oldermales from the Tromsø Study. For
22 cancer exposed, one reference subject was identified, for 9
cancer exposed two reference subjects, for another 9 cancer
exposed three reference subjects, and for 10 cancer exposed
four reference subjects were identified.
The IR of VTE that occurred during the total study period
(i.e., from more than 2 years after cancer diagnosis) was
higher in the cancer-exposed subjects (IR: 3.7  103 p-y,
95% CI: 3.1–4.5) compared with the reference subjects (IR:
1.9  103 p-y, 95% CI: 1.7–2.2; ►Table 2). The cumulative
incidence proportion of VTE increased linearly during fol-
low-up for both cancer-exposed and reference subjects, but
with a steeper slope in cancer exposed (►Fig. 1). The IRs of
VTEs calculated for the periods  2 and 5 years after a
cancer diagnosis were all nearly twofold higher compared
with reference subjects (►Table 3). The absolute occurrence
of VTE was significantly higher in cancer-exposed compared
with reference subjects even when restricting observation
time to the period beyond 5 years after cancer diagnosis
(IRD: 1.3  103 p-y, 95% CI: 0.2–2.3).
In the single entities of cancer, we observed varying IRs of
VTE in the cancer-exposed subjects, highest in the hemato-
logical cancers (IR VTE  2 years after cancer diagnosis
6.5  103 p-y, 95% CI: 3.7–11.4). The corresponding IRRs
of VTE in hematological cancers compared with their refer-
ence subjects in the total study period were also high (IRR:
4.0, 95% CI: 2.0–7.9) (►Table 3). Thus, the steeper slope of the
cumulative incidence proportion of VTE in cancer-exposed
subjects compared with reference subjects was mainly dri-
ven by the VTEs in hematological cancers. The IRs of VTE in
subjects exposed to solid tumors were in general lower than
in hematological cancers, but remained higher than refer-
ence subjects in colorectal and the group of other solid
cancer types when VTEs that occurred at least 2 years after
cancer diagnosis were included (►Table 2). The IRs of VTE in
prostate and colorectal cancer resembled that observed in
the reference subjects by successive time since cancer diag-
nosis (►Table 2). We observed no residual confounding by
the aging since cancer diagnosis/index date (►Table 3).
The impact of initial cancer stage at diagnosis on the IR of
VTEs in subjects exposed to solid cancer types was assessed
in a separate analysis. The IRRs of VTE in subjects exposed to
regional spread and distant metastatic cancers were 2.4 (95%
Table 2 IRs and IRDs of VTE in cancer-exposed subjects and their matched reference subjects by increasing time since cancer
diagnosis
Total study period, i.e.,  2 y after cancer diagnosis  5 y after cancer diagnosis
Total
VTE, n
Person time,
y
IR per
1,000 p-y
(95% CI)
IRD
(95% CI)
IR per
1,000 p-y
(95% CI)
IRD
(95% CI)
All reference subjects
combined
321 165,180 1.9
(1.7–2.2)
Ref. 2.1
(1.8–2.4)
Ref.
All cancer-exposed
combined
110 30,021 3.7
(3.1–4.5)
1.8
(1.1 to 2.5)
3.3
(2.5–4.5)
1.3
(0.2 to 2.3)
Breast 19 8,098 2.3
(1.5–3.7)
0.9
(–0.3 to 2.0)
2.0
(1.0–4.1)
1.0
(–0.5 to 2.5)
Prostate 18 4,619 3.9
(2.5–6.2)
1.4
(–0.5 to 3.3)
3.3
(1.5–7.4)
0.3
(–2.6 to 3.2)
Colorectal 21 4,294 4.9
(3.2–7.5)
2.6
(0.5 to 4.8)
2.6
(1.1–6.4)
–0.6
(–3.1 to 1.9)
Other solid tumors 40 10,506 3.8
(2.8–5.2)
1.8
(0.6 to 3.1)
3.9
(2.5–6.2)
1.8
(0.0 to 3.7)
Hematological 12 1,853 6.5
(3.7–11.4)
4.9
(1.2 to 8.7)
8.0
(3.6–17.8)
6.3
(–0.3 to 12.7)
Abbreviations: CI, confidence interval; IR, incidence rate; IRD, incidence rate differences; p-y, person-year; Ref., reference; VTE, venous
thromboembolism.
Fig. 1 Cumulative incidence proportion of venous thromboembolism
(VTE) in cancer-exposed subjects and reference subjects. Death as well
as first and second cancer, respectively, is treated as competing risks
in reference subjects and cancer survivors.
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CI: 1.7–3.5) and 5.1 (95% CI: 2.7–9.5), respectively, compared
with their reference subjects for the period 2 years after
cancer diagnosis, which was higher than the subjects
exposed to localized disease (1.5, 95% CI: 1.1–2.0). The
IRRs for subjects exposed to initial regional spread or distant
metastatic cancer tended to be lower >5 years after cancer
diagnosis (►Table 4).
In the cancer-exposed subjects, 39.1% of the VTEs were
provoked as compared with 36.4% in the reference subjects.
This small excess of provoked VTE was not statistically
significant (p ¼ 0.62).
Discussion
In this population-based cohort, IRs of VTE in cancer-
exposed subjects alive 2 years after their cancer diagnosis
and free of VTE were compared with age- and gender-
matched reference subjects. The IR of VTE was higher in all
cancer-exposed subjects combined comparedwith the refer-
ence subjects in both study periods. However, in the solid
cancer types, the IR fell successively by increasing time after
cancer diagnosis resembling the IRs of VTE of their reference
subjects over time, whereas in hematological cancers the IR
of VTE remained higher in cancer-exposed subjects com-
pared with reference subjects throughout the study period.
Initial distant metastasis was associated with a fivefold
higher risk of developing a first time VTE more than 2 years
after cancer diagnosis.
The hematological cancers encompassed a large propor-
tion ofmultiplemyeloma and chronic lymphocytic leukemia,
which are incurable diseases repeatedly treated at relapses.
Myeloma is well known for the associated high risk of VTE,
and recent studies have shown that chronic lymphocytic
leukemia may also be associated with a high incidence of
VTE.4,36,37 The high long-term incidences of VTE in the
hematological cancers might be due to anticancer treat-
ments, but since IMID-based combination therapy typically
did not persist for years in the study period and guidelines
recommended thromboprophylaxis, other factors may also
contribute. It has been suggested that cancer cells contribute
to hypercoagulability by releasing procoagulant microvesi-
cles.38 This may be associated with disease activity, and the
activity fluctuates in the incurable hematological cancers.
Therefore, this may explain a persistently increased risk of
VTE several years after cancer diagnosis in the group of
hematological cancers. Along the same line, the observed
Table 3 Crude and adjusted IRRs of VTE in cancer-exposed subjects by increasing time since cancer diagnosis
Total study period, i.e., > 2 y after cancer
diagnosis
> 5 y after cancer diagnosis
IRR,
crude
95% CI IRR,
adjusteda
95% CI IRR,
crude
95% CI IRR,
adjusteda
95% CI
All reference subjects
combined
Ref. – Ref. – Ref. – Ref. –
All cancer-exposed
combined
1.8 1.5–2.2 1.8 1.5–2.2 1.8 1.4–2.4 1.8 1.4–2.4
Breast 1.7 1.1–2.7 1.7 1.0–2.6 2.6 1.3–5.0 2.5 1.3–4.9
Prostate 1.4 0.9–2.3 1.4 0.9–2.3 1.4 0.7–2.9 1.5 0.7–2.9
Colorectal 1.7 1.1–2.7 1.7 1.0–2.6 0.8 0.3–1.8 0.8 0.3–1.8
Other solid cancer 2.1 1.3–3.3 2.1 1.3–3.3 2.1 1.3–3.3 2.1 1.3–3.3
Hematological 4.0 2.0–7.9 4.2 2.2–8.1 4.7 1.9–11.6 5.2 2.1–12.4
Abbreviations: CI, confidence interval; IRR, incidence rate ratios; Ref., reference; VTE, venous thromboembolism.
aAdjusted for age since study entry.
Table 4 Crude and adjusted IRRs of VTE stratified on initial cancer stage in cancer-exposed subjects compared with their controls
by increasing time since cancer diagnosis
Total study period, i.e., > 2 y after cancer diagnosis > 5 y after cancer diagnosis
VTE (n) IRR,
crude
95% CI IRR,
adjusteda
95% CI IRR,
crude
95% CI IRR,
adjusteda
95% CI
Localized disease 43 1.5 1.1–2.0 1.2 0.6–2.2 2.0 1.3–2.9 2.0 1.0–4.2
Regional spread 36 2.4 1.7–3.5 1.9 1.0–3.6 1.5 0.8–2.7 1.4 0.5–3.9
Distant metastasis 13 5.1 2.7–9.5 6.3 1.4–28.5 3.7 1.2–11.3 3.3 1.0–10.8
Actively coded
“Unknown stage”
18 1.4 0.9–2.2 0.8 0.2–3.2 1.8 1.0–3.3 0.8 0.1–5.6
Abbreviations: CI, confidence interval; IRR, incidence rate ratios; Ref., reference; VTE, venous thromboembolism.
aAdjusted for age since study entry and cancer type.
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persistently higher risk of VTE in subjects exposed to initial
metastatic cancer is probably, still to some degree, attribu-
table to cancer activity or treatments.
It is relevant to appreciate the validated outcomes in our
study since a validation study has shown that discharge
diagnoses of VTE from the National Patient Registry had a
positive predictive value of approximately 75%.35 Conse-
quently direct comparison of IRs of VTE in this study with
other studies is difficult. A recent population-based Swedish
study on time-dependent risk of VTE in breast cancer
patients found a 5-year cumulative incidence of 4.0% in
breast cancer patients, while in age-matched controls the
5-year cumulative incidence of VTE was 1.1%. The presented
measures of association were calculated from date of cancer
diagnosis, thus encompassing the large proportion of VTEs
that occurred during the first year of the study period.14 As
we started our study 2 years after cancer diagnosis and
further analyzed at points corresponding to 5 years after
cancer diagnosis, the former VTEs did not contribute to the
association measures in our study, and consequently the IRs
of VTEwere onlymarginally higher in breast cancer–exposed
subjects compared with their reference subjects. In the
Swedish study, the cumulative incidence curves of VTE
that occurred later than 2 years after breast cancer/index
date is only slightly steeper for the breast cancer exposed
than for the matched cohort reflecting marginally increased
risk of VTE in breast cancer–exposed subjects, in accordance
with our results. In a Danish population-based cohort study,
the reported IRs of VTE that occurredmore than 2 years after
cancer diagnosis were in general higher than we observed.3
Their use of discharge diagnoses from the National Patient
Registry, a broader definition of VTE and no censoring in case
of a second primary cancer diagnosis, may explain this,
although the variation is minor. A recent Danish popula-
tion-based study on VTE in prostate cancer found that a low
to moderate comorbidity in combination with cancer could
increase the risk of VTE more than expected from their
individual effects.39 The reported rates and rate ratios of
VTEwere similar to our results. However, we did not have the
opportunity to include comorbidity in our study, which
would have been beneficial.
The results from our study should be interpreted within
its limitations, of which the lack of information on comor-
bidity, anticoagulation, and chemotherapy are the most
important. Furthermore, we have too few events in some
groups to give meaningful estimates of IR and associated
association measures, which is also the reason why hema-
tological cancers were combined in one group despite their
varying phenotypes and risks of VTE. The myeloproliferative
and myelodysplastic disorders were not included because
theywere not available in the registries, but wewould expect
the number of VTEs to be very limited in these groups. We
cannot rule out misclassification due to second primary
cancers, but this would probably be nondifferential and
only comprise a minor proportion which most probably
would not affect the presented estimates of occurrence
and association. Another limitation is the inability to obtain
valid information on cancer relapses from the national
cancer registries and we may, therefore, overestimate the
IRs of VTE in the cancer-exposed subjects. This would
expectedly, in particular, be an important factor among
those exposed to hematological cancer types. On the other
hand, despite the potential overestimation of IR of VTE in the
cancer-exposed subjects, the IRs of VTE in subjects exposed
to breast, colorectal, and prostate cancer were not signifi-
cantly higher compared with their reference subjects 5 years
after the cancer diagnosis.
We know from unpublished data that 127 of VTEs
observed in the STAC cohort occurred within 1 year before
a first cancer diagnosis. Seventeen of these VTEs counted as
events among reference subjects in this study; when com-
pared with the total number of 321 VTEs in the reference
subjects, they will have a minor effect on the resulting
increased IR of VTE in the reference group and would draw
our results toward the null hypothesis. The cancer-exposed
group is a mix of cured and uncured patients, and the risk of
VTE years after a cancer diagnosis would expectedly differ
by this fact as reflected in the different risks of VTE
according to cancer types and initial cancer stage. The
proportion of cured and uncured patients in our cohort
should, however, resemble the mix of cancer patients
usually seen in hospitals.
Successively improved cancer treatments and accelerated
cancer-diagnosing programs have increased the proportion
of 5-year cancer survivors steadily during the past years.40
With these recent advances, it is becoming increasingly
relevant to describe health among cancer survivors. Our
observations are particularly relevant for the cancer patients
having survived to be discharged from the oncologic out-
patient clinics, whichwould be at 3 to 5 years formost cancer
types (in the Danish health care system).
To the best of our knowledge, this is the first population-
based study to specifically investigate the incidence of VTE in
subjects exposed to cancer being alive when the acute effect
of the cancer and its treatments on the riskof VTE attenuated
some years after the diagnosis. In conclusion, our study
indicates that the risk of a first VTE in cancer-exposed
subjects alive more than 2 years after their cancer was
diagnosed is modestly elevated compared with the back-
ground population, a finding mainly due to sustained VTE
occurrence in the hematological cancers.
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